| Item Type | Name |
|
Concept
|
Survival Analysis
|
|
Concept
|
Survival Rate
|
|
Concept
|
Cell Survival
|
|
Concept
|
Disease-Free Survival
|
|
Academic Article
|
Hematopoietic growth factors signal through the formation of reactive oxygen species.
|
|
Academic Article
|
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
|
|
Academic Article
|
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer.
|
|
Academic Article
|
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
|
|
Academic Article
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
|
|
Academic Article
|
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
|
|
Academic Article
|
Lung carcinoma in African Americans.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
|
Academic Article
|
Protein kinase C beta in malignant pleural mesothelioma.
|
|
Academic Article
|
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
|
|
Academic Article
|
The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre.
|
|
Academic Article
|
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
|
|
Academic Article
|
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.
|
|
Academic Article
|
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
|
|
Academic Article
|
Differential expression of RON in small and non-small cell lung cancers.
|
|
Academic Article
|
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
|
|
Academic Article
|
Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer.
|
|
Academic Article
|
CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer.
|
|
Academic Article
|
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
|
Academic Article
|
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
|
|
Academic Article
|
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
|
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
|
Academic Article
|
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
|
|
Academic Article
|
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.
|
|
Academic Article
|
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
|
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
|
Academic Article
|
Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.
|
|
Academic Article
|
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
|
|
Academic Article
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
|
Academic Article
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
|
Academic Article
|
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
|
|
Academic Article
|
A new PET/CT volumetric prognostic index for non-small cell lung cancer.
|
|
Academic Article
|
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
|
|
Academic Article
|
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
|
|
Academic Article
|
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
|
|
Academic Article
|
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
|
|
Academic Article
|
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
|
|
Academic Article
|
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
|
|
Academic Article
|
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
|
|
Academic Article
|
Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.
|
|
Academic Article
|
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
|
|
Academic Article
|
Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
|
|
Academic Article
|
2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.
|
|
Academic Article
|
Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.
|
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
|
Academic Article
|
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.
|
|
Academic Article
|
RLIP inhibition suppresses breast-to-lung metastasis.
|
|
Academic Article
|
Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
|
|
Academic Article
|
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
|
|
Academic Article
|
Targeting RLIP with CRISPR/Cas9 controls tumor growth.
|
|
Academic Article
|
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.
|
|
Academic Article
|
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
|
|
Academic Article
|
The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
|
|
Academic Article
|
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.
|
|
Academic Article
|
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
|
|
Academic Article
|
RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells.
|
|
Academic Article
|
Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy.
|
|
Academic Article
|
Disparate outcomes in nonsmall cell lung cancer by immigration status.
|
|
Academic Article
|
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
|
|
Academic Article
|
Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer.
|
|
Academic Article
|
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
|
|
Academic Article
|
Biologically Active Volume of Disease (BaVD) Predicts for Survival in Metastatic Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
|
|
Grant
|
Role of Paxillin in Lung Cancer
|